Data S1. Flow diagram of trials.

Data S2. Characteristics of studies included in the meta-analysis.

Data S3. Flow diagram of the selection processof adverse events (AEs).

Data S4. Risk differences (99% CIs) for adverse events associated with at least one dose of LCM. Significant estimates are shown in bold.

Figure S1. Number needed to harm at LCM dosesof 200, 400, and 600 mg for the AEs fatigue, nausea, vomitingand tremor, which were significantly associated with at least onedose of the experimental drug.

Figure S2. Frequency of AEs among patients randomized to placebo.

epi3589_sm_DocumentS1.doc29KSupporting info item
epi3589_sm_DocumentS2.doc86KSupporting info item
epi3589_sm_DocumentS3.doc29KSupporting info item
epi3589_sm_DocumentS4.doc34KSupporting info item
epi3589_sm_FigS1.tif799KSupporting info item
epi3589_sm_FigS2.tif808KSupporting info item

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.